Market Place
Sourcing Support
Sight Sciences to Present at Morgan Stanley Healthcare Conference
26 Aug 2025 //
GLOBENEWSWIRE
Sight Sciences Reports Q2 2025 Results, Boosts Full-Year Revenue
07 Aug 2025 //
GLOBENEWSWIRE
Sight Sciences`s TearCare® System`s for Meibomian Gland Disease
30 Jul 2025 //
GLOBENEWSWIRE
Sight Sciences Reveals 24-Month SAHARA RCT Results on TearCare
29 Jul 2025 //
GLOBENEWSWIRE
Sight Sciences to Present at Stifel 2025 Ophthalmology Forum
14 May 2025 //
GLOBENEWSWIRE
Sight Sciences Reports Q1 2025 Results, Reaffirms 2025 Guidance
08 May 2025 //
GLOBENEWSWIRE
Sight Sciences to Report Q1 2025 Financial Results on May 8
24 Apr 2025 //
GLOBENEWSWIRE
Sight Sciences Announces the Release of its Sustainability Report
23 Apr 2025 //
GLOBENEWSWIRE
Sight Sciences Appoints Gary Burbach to its Board of Directors
22 Apr 2025 //
GLOBENEWSWIRE
Sight Sciences to Debut Omni® Edge Surgical System at 2025 ASCRS
21 Apr 2025 //
GLOBENEWSWIRE
Sight Sciences to Present at 24th Annual Needham Healthcare Conf
25 Mar 2025 //
GLOBENEWSWIRE
Sight Sciences Reports Q4, FY24 Results, Issues FY25 Guidance
05 Mar 2025 //
GLOBENEWSWIRE
Sight Sciences to Present Clinical Data on OMNI® at 2025 AGS Meet
24 Feb 2025 //
GLOBENEWSWIRE
Sight Sciences to Report 2024 Financial Results on March 5, 2025
19 Feb 2025 //
GLOBENEWSWIRE
Sight Sciences To Present At Citi’s 2025 Unplugged MedTech Event
13 Feb 2025 //
GLOBENEWSWIRE
Sight Sciences Shares Preliminary 2024 Financial Performance
14 Jan 2025 //
GLOBENEWSWIRE
Sight Sciences Confirms 36-Month OMNI Effectiveness For Glaucoma
07 Jan 2025 //
GLOBENEWSWIRE
Sight Sciences Announces Budget Impact Analysis of TearCare
19 Dec 2024 //
GLOBENEWSWIRE
Sight Sciences To Present At Piper Sandler 36th Annual Conference
19 Nov 2024 //
GLOBENEWSWIRE
Sight Sciences Appoints MK Raheja & Brenton Taylor to EVP Roles
07 Nov 2024 //
GLOBENEWSWIRE
Sight Sciences Q3 2024 Results, Lowers Expense Guidance
07 Nov 2024 //
GLOBENEWSWIRE
Sight Sciences To Report Q3 Financial Results On November 7
17 Oct 2024 //
GLOBENEWSWIRE
TearCare Treatment Improved Outcomes In Dry Eye Disease Trial
14 Oct 2024 //
GLOBENEWSWIRE
Sight Sciences To Present At Morgan Stanley Global Healthcare Conference
20 Aug 2024 //
GLOBENEWSWIRE
Sight Sciences Reports Q2 2024 Results And Updates 2024 Guidance
01 Aug 2024 //
GLOBENEWSWIRE
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
18 Jul 2024 //
GLOBENEWSWIRE
Sight Sciences Announces the Release of its First Sustainability Report
10 Jun 2024 //
GLOBENEWSWIRE
Sight Sciences: ROMEO Analysis Shows OMNI Efficacy Across Glaucoma Types
28 May 2024 //
GLOBENEWSWIRE
Sight Sciences: 12-Month RCT Data On TearCare For Dry Eye Disease
28 May 2024 //
GLOBENEWSWIRE
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Sight Sciences Q1 2024 Results, FY2024 Guidance Reaffirmed
02 May 2024 //
GLOBENEWSWIRE
Sight Sciences Wins $34M Patent Verdict Against Alcon`s Hydrus
29 Apr 2024 //
GLOBENEWSWIRE
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
18 Apr 2024 //
GLOBENEWSWIRE
Sight Sciences Announces Publication of Large-Scale MIGS Study
10 Apr 2024 //
GLOBENEWSWIRE
Sight Sciences Announces the Results of GEMINI Trial at the 2024 ASCRS Meeting
02 Apr 2024 //
GLOBENEWSWIRE
Sight Sci to Present at the Upcoming 23rd Annual Needham Healthcare Conference
26 Mar 2024 //
GLOBENEWSWIRE
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
Sight Sciences Announces Launch of the Ergo-Series of the OMNI Surgical System
14 Feb 2024 //
GLOBENEWSWIRE
Sight Sciences Announces the Closing of up to $65M Secured Credit Facility
23 Jan 2024 //
GLOBENEWSWIRE
Sight Sciences Announces Unaudited Fourth Quarter and Full Year 2023 Highlights
08 Jan 2024 //
GLOBENEWSWIRE
Sight Sciences Announces Withdrawal of LCDs on Micro-Invasive Glaucoma Surgery
28 Dec 2023 //
GLOBENEWSWIRE
Sight Sciences Announces the Publication of Results of the SAHARA Clinical Trial
18 Dec 2023 //
GLOBENEWSWIRE
Sight Sciences Announces the Acceptance for Publication of GEMINI 2
08 Dec 2023 //
GLOBENEWSWIRE
Sight Sciences Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Sight Sciences to Report Third Quarter 2023 Financial Results
24 Oct 2023 //
GLOBENEWSWIRE
Sight Sciences to Host SAHARA 6 Month RCT Results Reception
19 Oct 2023 //
GLOBENEWSWIRE
Sight Sciences Announces Presentation of Phase I Results of the SAHARA Trial
12 Oct 2023 //
GLOBENEWSWIRE
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS
03 Oct 2023 //
GLOBENEWSWIRE
Sight Sciences Appoints Matt Link as Chief Commercial Officer
11 Sep 2023 //
GLOBENEWSWIRE
Sight Sciences Provides Revenue Guidance for the Third Quarter of 2023
11 Sep 2023 //
GLOBENEWSWIRE
Sight Sciences to Present at the Upcoming Morgan Stanley 21st Annual Conference
30 Aug 2023 //
GLOBENEWSWIRE
Sight Sciences Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
GLOBENEWSWIRE
Sight Sciences Announces Results and Primary Endpoint Successfully Met in SAHARA
20 Jul 2023 //
GLOBENEWSWIRE
Sight Sciences to Report Second Quarter 2023 Financial Results on August 3, 2023
20 Jul 2023 //
GLOBENEWSWIRE
Cigna Expands Coverage of Glaucoma Surgical Procedures to Include Canaloplasty
21 Jun 2023 //
GLOBENEWSWIRE
Sight Sciences 2 Year Multicenter Study Results Show Sustained Reductions in IOP
23 May 2023 //
GLOBENEWSWIRE
Sight Sciences Announces 12-month Results from the First (MIGS) (RWD)
06 May 2023 //
GLOBENEWSWIRE
Sight Sciences Reports 1Q 2023 FYR and Reaffirms Guidance for Full Year 2023
04 May 2023 //
GLOBENEWSWIRE
Sight Sciences` Glaucoma & Dry Eye Technologies to be Featured at the 2023 ASCRS
01 May 2023 //
GLOBENEWSWIRE
